These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 17122530

  • 1. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
    Ollendorf DA, Lidsky L.
    Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
    [Abstract] [Full Text] [Related]

  • 2. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
    Carter CT, Waters HC, Smith DB.
    Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S, Stolte SB, van den Brink GR, Ponsioen CY, Fockens P, D'Haens GR, Löwenberg M.
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
    [Abstract] [Full Text] [Related]

  • 11. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.
    Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A.
    Am J Gastroenterol; 2016 Jan; 111(1):15-23. PubMed ID: 26195179
    [Abstract] [Full Text] [Related]

  • 12. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.
    J Med Econ; 2012 Jan; 15(2):264-75. PubMed ID: 22115327
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The cost of hospitalization in Crohn's disease.
    Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL.
    Am J Gastroenterol; 2000 Feb; 95(2):524-30. PubMed ID: 10685762
    [Abstract] [Full Text] [Related]

  • 16. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN.
    Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944
    [Abstract] [Full Text] [Related]

  • 17. Dose intensification with infliximab in patients with rheumatoid arthritis.
    Berger A, Edelsberg J, Li TT, Maclean JR, Oster G.
    Ann Pharmacother; 2005 Dec; 39(12):2021-5. PubMed ID: 16288073
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.